Glycogen phosphorylase inhibition improves beta cell function

British Journal of Pharmacology

Volumn 175, Issue 2, 2018, Pages 301-319

  Nagy, Lilla ^a,b   Márton, Judit ^a   Vida, András ^a,d   Kis, Gréta ^a   Bokor, Éva ^c   Kun, Sándor ^c   Gönczi, Mónika ^a   Docsa, Tibor ^a   Tóth, Attila ^a   Antal, Miklós ^a,i   Gergely, Pál ^a   Csóka, Balázs ^e,f   Pacher, Pal ^g   Somsák, László ^c   Bai, Péter ^a,d,h  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b MTA de Cell Biology and Signaling Research Group   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d MTA DE Lendulet Laboratory of Cellular Metabolism   (Hungary)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f The State University of New Jersey   (United States)

^g NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^h UNIVERSITY OF DEBRECEN   (Hungary)

ⁱ INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

3 BETA GLUCOPYRANOSYL 5 (2 NAPHTHYL) 1,2,4 TRIAZOLE; 5 CHLORO N [2 HYDROXY 3 (METHOXYMETHYLAMINO) 3 OXO 1 (PHENYLMETHYL)PROPYL] 1H INDOLE 2 CARBOXAMIDE; ANTIDIABETIC AGENT; BEVA 335; CP 316819; ENZYME INHIBITOR; GLYCOGEN PHOSPHORYLASE; GLYCOGEN PHOSPHORYLASE INHIBITOR; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; KB 228; N (3,5 DIMETHYLBENZOYL) N' (GLUCOPYRANOSYL)UREA; PROTEIN KINASE B; S6 KINASE; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; GLYCOGEN; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CALCIUM SIGNALING; CELL SURVIVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLYCOGEN ANALYSIS; GLYCOGEN METABOLISM; GLYCOLYSIS; INSULIN RELEASE; INSULINOMA; INTRACELLULAR SIGNALING; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; DRUG EFFECT; METABOLISM; MITOCHONDRION; PANCREAS ISLET;

ANIMALS; CALCIUM SIGNALING; CELLS, CULTURED; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; GLYCOLYSIS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MITOCHONDRIA; RECEPTOR, INSULIN;

EID: 85020538619     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13819     Document Type: Article

References (62)

1. Abdul-Ghani MA (2013). Type 2 diabetes and the evolving paradigm in glucose regulation. The American journal of managed care 19: S43–50.
2. Agius L (2007). New hepatic targets for glycaemic control in diabetes. Best Pract Res Clin Endocrinol Metab 21: 587–605.
3. Agius L (2015). Role of glycogen phosphorylase in liver glycogen metabolism. Mol Aspects Med 46: 34–45.
4. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015a). The concise guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol 172: 5870–5903.
5. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The concise guide to PHARMACOLOGY 2015/16: Catalytic receptors. Br J Pharmacol 172: 5979–6023.
6. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The concise guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
7. Bai P (2015). Biology of poly(adp-ribose) polymerases: the factotums of cell maintenance. Mol Cell 58: 947–958.
8. Bai P, Canto C, Brunyanszki A, Huber A, Szanto M, Cen Y et al. (2011). PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab 13: 450–460.
9. Baker DJ, Timmons JA, Greenhaff PL (2005). Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes 54: 2453–2459.
10. Baker DJ, Greenhaff PL, MacInnes A, Timmons JA (2006). The experimental type 2 diabetes therapy glycogen phosphorylase inhibition can impair aerobic muscle function during prolonged contraction. Diabetes 55: 1855–1861.
11. Bernal-Mizrachi E, Fatrai S, Johnson JD, Ohsugi M, Otani K, Han Z et al. (2004). Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells. Journal of Clinical Investigation 114: 928–936.
12. Bokor E, Docsa T, Gergely P, Somsak L (2013). C-glucopyranosyl-1,2,4-triazoles as new potent inhibitors of glycogen phosphorylase. ACS Med Chem Lett 4: 612–615.
13. Bokor E, Kun S, Docsa T, Gergely P, Somsák L (2015). 4(5)-Aryl-2-C-glucopyranosyl-imidazoles as new nanomolar glucose analogue inhibitors of glycogen phosphorylase. ACS Med Chem Lett 6: 1215–1219.
14. Boucher J, Kleinridders A, Kahn CR (2014). Insulin Receptor Signaling in Normal and Insulin-Resistant States. Cold Spring Harbor Perspectives in Biology 6: a009191.
15. Cerf ME (2013). Beta Cell Dysfunction and Insulin Resistance. Frontiers in Endocrinology 4: 37.
16. Cheng Z, Tseng Y, White MF (2010). Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 21: 589-598.
17. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
18. Czikora A, Lizanecz E, Bako P, Rutkai I, Ruzsnavszky F, Magyar J et al. (2012). Structure-activity relationships of vanilloid receptor agonists for arteriolar TRPV1. Br J Pharmacol 165: 1801–1812.
19. Doherty M, Malaisse WJ (2001). Glycogen accumulation in rat pancreatic islets: in vitro experiments. Endocrine 14: 303–309.
20. Elghazi L, Bernal-Mizrachi E (2009). Akt/PTEN: β-cell mass and pancreas plasticity. Trends in endocrinology and metabolism. TEM 20: 243–251.
21. Favaro E, Bensaad K, Chong MG, Tennant DA, Ferguson DJ, Snell C et al. (2012). Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab 16: 751–764.
22. Fujimoto K, Polonsky KS (2009). Pdx1 and other factors that regulate pancreatic β-cell survival. Diabetes, obesity & metabolism 11: 30–37.
23. Fuxreiter M (2012). Fuzziness: linking regulation to protein dynamics. Molecular bioSystems 8: 168–177.
24. Graf R, Klessen C (1981). Glycogen in pancreatic islets of steroid diabetic rats. Carbohydrate histochemical detection and localization using an immunocytochemical technique. Histochemistry 73: 225–232.
25. Graf R, Tolken M (1984). Ultrastructural distribution of glycogen in pancreatic islets of steroid diabetic rats. Basic and applied histochemistry 28: 391–397.
26. Halban PA, Polonsky KS, Bowden DW, Hawkins MA, Ling C, Mather KJ et al. (2014). β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 37: 1751–1758.
27. Hayes JM, Kantsadi AL, Leonidas DD (2014). Natural products and their derivatives as inhibitors of glycogen phosphorylase: potential treatment for type 2 diabetes. Phytochemistry Reviews 13: 471–498.
28. Hellman B, Idahl LA (1969). Presence and mobilization of glycogen in mammalian pancreatic beta cells Endocrinology 84: 1–8.
29. Henke BR (2012). Inhibition of Glycogen Phosphorylase as a Strategy for the Treatment of Type 2 Diabetes. In: Jones RM, Thurston DE, Rotella D (eds). New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches, RSC drug discovery series edn: Royal Society of Chemistry. pp 324–365.
30. Humphrey RK, Yu SM, Flores LE, Jhala US (2010). Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and AKT kinases. J Biol Chem 285: 3406–3416.
31. Johnson D, Shepherd RM, Gill D, Gorman T, Smith DM, Dunne MJ (2007). Glucose-dependent modulation of insulin secretion and intracellular calcium ions by GKA50, a glucokinase activator. Diabetes 56: 1694–1702.
32. Johnson JD, Bernal-Mizrachi E, Alejandro EU, Han Z, Kalynyak TB, Li H et al. (2006). Insulin protects islets from apoptosis via Pdx1 and specific changes in the human islet proteome. Proceedings of the National Academy of Sciences of the United States of America 103: 19575–19580.
33. Kaneto H, Matsuoka T-a (2015). Role of Pancreatic Transcription Factors in Maintenance of Mature β-Cell Function. International Journal of Molecular Sciences 16: 6281–6297.
34. Karnovsky MJ (1971). Use of ferrocyanide-reduced osmium in electron microscopy. J Cell Biol 51: 146.
35. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
36. Lee WNP, Guo P, Lim S, Bassilian S, Lee ST, Boren J et al. (2004). Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. British Journal of Cancer 91: 2094–2100.
37. Liu S, Okada T, Assmann A, Soto J, Liew CW, Bugger H et al. (2009). Insulin signaling regulates mitochondrial function in pancreatic beta-cells. PLoS One 4: e7983.
38. MacDonald PE, Joseph JW, Rorsman P (2005). Glucose-sensing mechanisms in pancreatic beta-cells. Philos Trans R Soc Lond B Biol Sci 360: 2211–2225.
39. Malaisse WJ (2016). Role of glycogen metabolism in pancreatic islet beta cell function. Diabetologia 59: 2489–2491.
40. Malaisse WJ, Ladriere L, Cancelas J, Acitores A, Villanueva-Penacarrillo ML, Valverde I (2001). Pancreatic and hepatic glycogen content in normoglycemic and hyperglycemic rats. Mol Cell Biochem 219: 45–49.
41. Malaisse WJ, Maggetto C, Leclercq-Meyer V, Sener A (1993). Interference of glycogenolysis with glycolysis in pancreatic islets from glucose-infused rats. J Clin Invest 91: 432–436.
42. Malaisse WJ, Marynissen G, Sener A (1992). Possible role of glycogen accumulation in B-cell glucotoxicity. Metabolism 41: 814–819.
43. Malaisse WJ, Sener A, Koser M, Ravazzola M, Malaisse-Lagae F (1977). The stimulus-secretion coupling of glucose-induced insulin release. Insulin release due to glycogenolysis in glucose-deprived islets. Biochem J 164: 447–454.
44. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
45. Mir-Coll J, Duran J, Slebe F, García-Rocha M, Gomis R, Gasa R et al. (2016). Genetic models rule out a major role of beta cell glycogen in the control of glucose homeostasis. Diabetologia 59: 1012–1020.
46. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y et al. (1990). Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology 127: 126–132.
47. Nagy L, Docsa T, Szántó M, Brunyánszki A, Hegedűs C, Márton J et al. (2013). Glycogen phosphorylase inhibitor N-(3,5-dimethyl-benzoyl)-N′-(β-D-glucopyranosyl)urea improves glucose tolerance under normoglycemic and diabetic conditions and rearranges hepatic metabolism. PLoS One 8: e0069420.
48. Osz E, Somsak L, Szilagyi L, Kovacs L, Docsa T, Toth B et al. (1999). Efficient inhibition of muscle and liver glycogen phosphorylases by a new glucopyranosylidene-spiro-thiohydantoin. Bioorg Med Chem Lett 9: 1385–1390.
49. Rath VL, Ammirati M, Danley DE, Ekstrom JL, Gibbs EM, Hynes TR et al. (2000). Human liver glycogen phosphorylase inhibitors bind at a new allosteric site. Chemistry & biology 7: 677–682.
50. Rhodes CJ, White MF, Leahy JL, Kahn SE (2013). Direct autocrine action of insulin on beta-cells: does it make physiological sense? Diabetes 62: 2157–2163.
51. Robinson JM, Karnovsky ML, Karnovsky MJ (1982). Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation. The Journal of cell biology 95: 933–942.
52. Sarbassov DD, Ali SM, Sabatini DM (2005). Growing roles for the mTOR pathway. Curr Opin Cell Biol 17: 596–603.
53. Shang Y, Liu Y, Du L, Wang Y, Cheng X, Xiao W et al. (2009). Targeted expression of uncoupling protein 2 to mouse liver increases the susceptibility to lipopolysaccharide/galactosamine-induced acute liver injury. Hepatology 50: 1204–1216.
54. Sharma S, Leonard J, Lee S, Chapman HD, Leiter EH, Montminy MR (1996). Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF. J Biol Chem 271: 2294–2299.
55. Sharma R, Raduly Z, Miskei M, Fuxreiter M (2015). Fuzzy complexes: Specific binding without complete folding. FEBS Lett 589 (19 Pt A): 2533–2542.
56. Somsák L, Czifrák K, Tóth M, Bokor É, Chrysina ED, Alexacou KM et al. (2008a). New inhibitors of glycogen phosphorylase as potential antidiabetic agents. Curr Med Chem 15: 2933–2983.
57. Somsák L, Felföldi N, Kónya B, Hüse C, Telepó K, Bokor E et al. (2008b). Assessment of synthetic methods for the preparation of N-β-d-glucopyranosyl-N′-substituted ureas, −thioureas and related compounds. Carbohydr Res 343: 2083–2093.
58. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res 44 (D1): D1054–D1068.
59. Stalmans W, Bollen M, Toth B, Gergely P (1990). Short-term hormonal control of protein phosphatases involved in hepatic glycogen metabolism. Adv Enzyme Regul 30: 305–327.
60. Tartier L, Spenlehauer C, Newman HC, Folkard M, Prise KM, Michael BD et al. (2003). Local DNA damage by proton microbeam irradiation induces poly(ADP-ribose) synthesis in mammalian cells. Mutagenesis 18: 411–416.
61. Torres TP, Sasaki N, Donahue EP, Lacy B, Printz RL, Cherrington AD et al. (2011). Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs. J Pharmacol Exp Ther 337: 610–620.
62. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D et al. (2001). Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105: 745–755.